FoldRx Pharmaceuticals, founded in 2003, is a pioneering biopharmaceutical company focused on the discovery and development of disease-modifying drug therapies for protein misfolding diseases. Their mission, encapsulated in their slogan, aims at addressing the critical challenge of protein folding, a vital process essential for normal cellular function. Misfolded proteins, as detailed in their description, can lead to the accumulation of toxic intermediates or the loss of normal protein function, contributing to various diseases.
The company's approach involves first-in-class, small molecule therapeutics designed to tackle these intricate cellular challenges, positioning FoldRx Pharmaceuticals as a significant player in the biotech industry. Their recent financial highlight includes a substantial $29.00M venture round investment on 15 June 2010, backed by leading investors such as F-Prime Capital, Novartis Venture Fund, Alta Partners, HealthCare Ventures, Morgenthaler Ventures, TPG, and Novo Ventures. This solid financial support underscores strong market confidence in their innovative therapeutic pipeline.
